Press release
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Avidity Biosciences
"Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Facioscapulohumeral Muscular Dystrophy Therapeutics Market.
The report provides a detailed description of the Facioscapulohumeral Muscular Dystrophy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Facioscapulohumeral Muscular Dystrophy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Facioscapulohumeral Muscular Dystrophy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Facioscapulohumeral Muscular Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Facioscapulohumeral Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Facioscapulohumeral Muscular Dystrophy treatment market.
Learn More about the Clinical and Commercial Development Activities in the Facioscapulohumeral Muscular Dystrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Facioscapulohumeral Muscular Dystrophy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Facioscapulohumeral Muscular Dystrophy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Facioscapulohumeral Muscular Dystrophy (FSHD) Therapeutics Analysis
There are currently no disease-modifying treatments for FSHD; supportive care is the mainstay of managing FSHD. This care primarily occurs in the context of physical therapy and rehabilitation exercises. Managing pain and fatigue in FSHD patients is essential, as both symptoms can affect patient psychology. Chronic pain is manageable with analgesic and antidepressant therapy to improve the quality of life in FSHD patients
Several major pharma and biotech companies are developing therapies for Facioscapulohumeral Muscular Dystrophy. Several of the therapies are in the advanced stages of clinical development and are expected to hit the market in the near future.
Facioscapulohumeral Muscular Dystrophy (FSHD) Companies in the Therapeutics Market Include:
• Fulcrum Therapeutics
• Dyne Therapeutics.
• Hoffmann-La Roche
• aTyr Pharma, Inc.
• Avidity Biosciences, Inc.
And Many Others
Emerging and Marketed Facioscapulohumeral Muscular Dystrophy (FSHD) Therapies Covered in the Report Include:
• Losmapimod: Fulcrum Therapeutics
• DYNE-301: Dyne Therapeutics
• AOC 1020: Avidity Biosciences
• MC-DX4: miRecule
• Losmapimod: Fulcrum Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Facioscapulohumeral Muscular Dystrophy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Current Treatment Patterns
4. Facioscapulohumeral Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Facioscapulohumeral Muscular Dystrophy Late-Stage Products (Phase-III)
7. Facioscapulohumeral Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Facioscapulohumeral Muscular Dystrophy Discontinued Products
13. Facioscapulohumeral Muscular Dystrophy Product Profiles
14. Facioscapulohumeral Muscular Dystrophy Companies
15. Facioscapulohumeral Muscular Dystrophy Drugs
16. Dormant and Discontinued Products
17. Facioscapulohumeral Muscular Dystrophy Unmet Needs
18. Facioscapulohumeral Muscular Dystrophy Future Perspectives
19. Facioscapulohumeral Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market
Concussions Market
https://www.delveinsight.com/report-store/concussions-market
Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market
Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market
Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market
Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market
Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Avidity Biosciences here
News-ID: 3129533 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Facioscapulohumeral
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Massive Growth opportunity …
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle disorder characterized by progressive weakness of facial, shoulder, and upper arm muscles, and eventually lower body muscles. It is the third most common type of muscular dystrophy, affecting approximately 1 in 8,000 to 1 in 20,000 individuals worldwide.
FSHD is typically caused by abnormal expression of the DUX4 gene due to genetic mutations on chromosome 4. While there is currently no approved…
Facioscapulohumeral Muscular Dystrophy Market Expected to Evolve Through 2034 Am …
Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most prevalent forms of muscular dystrophy, characterized by progressive skeletal muscle weakness that initially affects the face, shoulders, and upper arms. The condition is genetically linked to abnormal expression of the DUX4 gene, most commonly caused by contraction of the D4Z4 repeat on chromosome 4. FSHD can significantly impact mobility, quality of life, and daily function, though disease progression varies widely among…
Facioscapulohumeral Muscular Dystrophy Market Set for Growth Through 2034, Drive …
Facioscapulohumeral Muscular Dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy, is a rare and progressive genetic disorder characterized by muscle weakness and atrophy, typically affecting the face, shoulder blades, and upper arms. With no approved disease-modifying therapies currently available, FSHD poses a significant unmet need for patients and healthcare systems globally.
DelveInsight's latest report, "Facioscapulohumeral Muscular Dystrophy - Market Insight, Epidemiology, and Market Forecast - 2034," offers an…
Facioscapulohumeral Muscular Dystrophy Clinical Trials, Treatment Drugs, Pipelin …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyn …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
Facioscapulohumeral Muscular Dystrophy Market Size, Share, Trends, Demand, Growt …
Global Facioscapulohumeral Muscular Dystrophy Market study by Data Bridge Market Research provides details about the market dynamics affecting the Facioscapulohumeral Muscular Dystrophy market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.
A number of estimations and calculations have been included in the first class Facioscapulohumeral Muscular Dystrophy market report by assuming definite base year and the…
